ストックスクリーナーアプリを入手
63.75
2.83%
-1.86
前日終値:
$65.61
開ける：
$66.57
24時間の取引高:
628.28K
Relative Volume:
1.09
時価総額：
$3.45B
収益：
$155.82M
当期純損益:
$-40.42M
株価収益率:
-89.79
EPS:
-0.71
ネットキャッシュフロー:
$3.58M
1週間 パフォーマンス:
-2.27%
1か月 パフォーマンス:
-4.24%
6か月 パフォーマンス:
-4.34%
1年 パフォーマンス:
+6.30%
1日の値動き範囲:
$63.46
$66.66
1週間の範囲:
$62.38
$67.00
52週間の値動き範囲:
$47.88
$107.37
Arcellx Inc Stock (ACLX) Company Profile
ACLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
63.75 | 3.45B | 155.82M | -40.42M | 3.58M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-03-07 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-04 | 繰り返されました | Needham | Buy |
| 2023-12-19 | 開始されました | Scotiabank | Sector Outperform |
| 2023-10-30 | 開始されました | TD Cowen | Outperform |
| 2023-10-17 | 開始されました | UBS | Buy |
| 2023-05-18 | 開始されました | Truist | Buy |
| 2023-04-14 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-14 | 開始されました | Stifel | Buy |
| 2023-02-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-13 | 再開されました | BofA Securities | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-27 | 開始されました | Needham | Buy |
| 2022-07-20 | 開始されました | Canaccord Genuity | Buy |
| 2022-03-01 | 開始されました | BofA Securities | Buy |
| 2022-03-01 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Arcellx Inc (ACLX) 最新ニュース
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - MSN
Arcellx (ACLX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Is Arcellx (ACLX) Poised to Capture Significant Market Share? - Yahoo Finance UK
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Large Increase in Short Interest - Defense World
(ACLX) Trading Advice - Stock Traders Daily
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention - Benzinga
Arcellx Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St
Arcellx Inc’s Anito-cel: A Promising Investment with Innovative Therapeutics and Market Potential - TipRanks
Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat
Financial Snapshot: Analyzing Arcellx Inc (ACLX)’s Key Ratio Metrics - The Dwinnex
Arcellx (NASDAQ:ACLX) Shares Down 5.4%What's Next? - MarketBeat
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Increases By 6.6% - MarketBeat
Taking a Closer Look At Arcellx Inc (ACLX) Following Its Recent Trade - Knox Daily
arcellx director kavita patel sells $96,854 in stock - MSN
Financial Review: Arcellx (NASDAQ:ACLX) versus C4 Therapeutics (NASDAQ:CCCC) - Defense World
arcellx director kavita patel sells $96,854 in stock By Investing.com - Investing.com Australia
(ACLX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Brokerages Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - MarketBeat
Moody Aldrich Partners LLC Sells 16,122 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Analysts Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - Defense World
Vanguard Group Inc's Strategic Acquisition of Arcellx Inc Shares - GuruFocus.com
Stifel maintains Buy on Arcellx shares, target at $122 - MSN
Stifel maintains Buy on Arcellx shares, target at $122 By Investing.com - Investing.com Australia
(ACLX) On The My Stocks Page - Stock Traders Daily
Cantor Fitzgerald Estimates Arcellx FY2025 Earnings - Defense World
Brokers Issue Forecasts for Arcellx FY2025 Earnings - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Sees Significant Growth in Short Interest - Defense World
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 6.6% - MarketBeat
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy - Seeking Alpha
Arcellx director Kavita Patel sells $98,801 in stock By Investing.com - Investing.com Australia
Arcellx, Inc. (NASDAQ:ACLX) Director Kavita Patel Sells 1,500 Shares - MarketBeat
Arcellx director Kavita Patel sells $98,801 in stock - Investing.com India
(ACLX)Analyzing Arcellx's Short Interest - Benzinga
Oversold Conditions For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 in Stock - MarketBeat
Arcellx's chief medical officer sells shares worth $581,315 By Investing.com - Investing.com Australia
Arcellx Inc (ACLX) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):